TAM895755_Supplementary_material_CLN – Supplemental material for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

Adamo, Vincenzo; Ricciardi, Giuseppina Rosaria Rita; Giuffrida, Dario; Scandurra, Giuseppa; Russo, Antonio; Blasi, Livio; Spadaro, Pietro; Iacono, Carmelo; Soto Parra, Hector J.; Savarino, Antonino; Ferraú, Francesco; Zerilli, Filippo; Verderame, Francesco; Butera, Alfredo; Santangelo, Carlo; Franchina, Veronica; Caruso, Michele

doi:10.25384/SAGE.11417742.v1

TAM895755_Supplementary_material_CLN.docx (13.4 kB)

TAM895755_Supplementary_material_CLN – Supplemental material for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

journal contribution

posted on 2019-12-20, 13:07 authored by Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio Blasi, Pietro Spadaro, Carmelo Iacono, Hector J. Soto Parra, Antonino Savarino, Francesco Ferraú, Filippo Zerilli, Francesco Verderame, Alfredo Butera, Carlo Santangelo, Veronica Franchina, Michele Caruso

Supplemental material, TAM895755_Supplementary_material_CLN for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study by Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio Blasi, Pietro Spadaro, Carmelo Iacono, Hector J. Soto Parra, Antonino Savarino, Francesco Ferraú, Filippo Zerilli, Francesco Verderame, Alfredo Butera, Carlo Santangelo, Veronica Franchina and Michele Caruso in Therapeutic Advances in Medical Oncology